Ipilimumab is a humanized IgG1 monoclonal antibody that binds to CTLA-4 in the B7 interaction domain, mediating steric hindration to block the binding of CTLA-4 to B7, and is the first CTLA-4 antibody drug used in advanced melanoma. This evidence concerns the gene CD80 and melanoma.